{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Plimack ER"],"funding":["NCI NIH HHS"],"pagination":["1895-901"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4050203"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(18)"],"pubmed_abstract":["Purpose
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequently adopted in practice because of concerns regarding toxicity and delay to cystectomy. We hypothesized that three cycles of neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) would be safe, shorten the time to surgery, and yield similar pathologic complete response (pT0) rates compared with historical controls.Patients and methods
Patients with cT2-T4a and N0-N1 MIBC were eligible and received three cycles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection. The primary end point was pT0 rate. Telomere length (TL) and p53 mutation status were correlated with response and "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity."],"pmcid":["PMC4050203"],"funding_grant_id":["P30CA00692","P30 CA056036","P30 CA006927","3 P30 CA-006927-47S4"],"pubmed_authors":["Brennan TA","Palma N","Lallas CD","Wong YN","Ross EA","Trabulsi EJ","Uzzo RG","Hudes GR","Greenberg RE","Viterbo R","Mehrazin R","Hoffman-Censits JH","Kelly WK","Kutikov A","Dotan E","Boorjian SA","Plimack ER","Lin J","Chen DY","Dulaimi E"],"additional_accession":[]},"is_claimable":false,"name":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.","description":"Purpose
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequently adopted in practice because of concerns regarding toxicity and delay to cystectomy. We hypothesized that three cycles of neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) would be safe, shorten the time to surgery, and yield similar pathologic complete response (pT0) rates compared with historical controls.Patients and methods
Patients with cT2-T4a and N0-N1 MIBC were eligible and received three cycles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection. The primary end point was pT0 rate. Telomere length (TL) and p53 mutation status were correlated with response and ","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jun","modification":"2025-04-22T00:54:05.682Z","creation":"2019-03-27T01:29:44Z"},"accession":"S-EPMC4050203","cross_references":{"pubmed":["24821881"],"doi":["10.1200/JCO.2013.53.2465","10.1200/jco.2013.53.2465"]}}